Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action

Critically ill COVID-19 patients have a clear pattern of inflammation and hypercoagulable state. The main aim of the study was to evaluate the outcome of severe COVID-19 patients basing on prothrombotic risk factors (i.e. D-dimer). We also evaluated the impact of different doses of low molecular weight heparin (LMWH) on incidence of major bleedings.

Source: Thrombosis Research - September 12, 2020 Category: Hematology Authors: Vittorio Pavoni, Lara Gianesello, Maddalena Pazzi, Caterina Stera, Tommaso Meconi, Francesca Covani Frigieri Tags: Full Length Article Source Type: research